Novel Oxadiazole Thioglycosides as Potential Anti- Acinetobacter Agents

Novel Oxadiazole Thioglycosides as Potential Anti-Acinetobacter Agents

The glycosylation of 1,3,4-oxadiazole-2-thiones has been performed with peracetylated β-pyranosyl bromide in the presence of potassium carbonate. Deprotection of acetylated thioglycosides was necessary for increasing their antibacterial effects. The structures of nucleosides were confirmed by 1H NMR, 13C NMR and HRMS. The anomeric protons of nucleosides c1-4 were assigned to the doublet, confir...

novel oxadiazole thioglycosides as potential anti- acinetobacter agents

the glycosylation of 1,3,4-oxadiazole-2-thiones has been performed with peracetylated β-pyranosyl bromide in the presence of potassium carbonate. deprotection of acetylated thioglycosides was necessary for increasing their antibacterial effects. the structure of nucleosides were confirmed by 1h nmr, 13c nmr and hrms. the anomeric protons of nucleosides c1–4 were assigned to the doublet, confirm...

Synthesis of novel 1,3,4-oxadiazole derivatives as potential antimicrobial agents.

Some new 3-acetyl-5-(3-chloro-1-benzo[b]thiophen-2-yl)-2-substituted phenyl-2,3-dihydro-1,3,4-oxadiazoles and 2-(3-chloro-1-benzo[b]thiophen-2-yl)-5-substituted phenyl-1,3,4-oxadiazoles have been synthesized and evaluated for antimicrobial activity. Initially, 3-chloro-1-benzo[b]thiophene-2-carbonyl chloride (1) was prepared from cinnamic acid in the presence of chlorobenzene and thionyl chlori...

Synthesis of some 1,3,4-oxadiazole derivatives as potential anti-inflammatory agents

The synthesis of some new 1,3,4-oxadiazole derivatives and 1,2,4-triazine-5-one has been described. IR, H NMR and mass spectral data support the structures of newly synthesized compounds. All the compounds have been tested in vivo for their anti-inflammatory activity by carrageenin-induced rat paw edema method. The compounds, which show good antiinflammatory activity, have been screened for the...

synthesis of new 1,3,4-oxadiazole derivatives as anti-hiv agents